Targeting PD-L1 in non-small cell lung cancer using CAR T cells
Abstract Antibodies against programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the landscape of therapies for non-small cell lung carcinoma (NSCLC); however, the majority of patients do not respond to these agents. In addition, hyperprogressive disease (HPD) deve...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | 英语 |
| 出版: |
2020
|
| 在線閱讀: | https://doi.org/10.1038/s41389-020-00257-z https://www.nature.com/articles/s41389-020-00257-z.pdf |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
成為第一個發表評論!